AmoyDx® NGS Panels: Decentralized, Fast, and Reliable

The AmoyDx® NGS portfolio features comprehensive panels designed to deliver high sensitivity, fast turnaround times, and practical usability for decentralized precision oncology. Covering a broad range of cancers and sample types, the panels are optimized for FFPE tissue, plasma cfDNA, germline, and hematologic specimens, supporting laboratories in bringing high-quality testing closer to patients.

A cornerstone of the portfolio is the proprietary.

HANDLE® (Halo-shape ANnealing and Defer-Ligation Enrichment) Technology. This innovative, one-tube workflow simplifies the entire NGS process, making it as convenient as PCR. It significantly reduces hands-on time to less than one hour and enables a total library preparation time of just five hours, lowering the cost barrier for in-house NGS testing.

Key Portfolio Highlights:

• Comprehensive Clinical Coverage: Focused and broad panels are available for key applications, including biomarker detection in lung, colorectal , breast , ovarian , prostate , and hematologic cancers.
• Multiple Sample Types: Panels are optimized for use with FFPE tissue, liquid biopsy (cfDNA), and blood (germline) samples.
• Automated, User-Friendly Analysis: The AmoyDx NGS Data Analysis System (ANDAS) provides a local, secure server solution with a user-friendly interface for automated data interpretation and reporting.
• Validated and Trusted Performance: Panels are validated for clinical sample conditions, with over 40 kits CE-IVDD marked and multiple CE-IVDR projects ongoing. AmoyDx delivers over 1,000,000 diagnostic tests annually worldwide and collaborates with more than 20 leading pharmaceutical partners.

AmoyDx® continues to expand its NGS portfolio to empower decentralized precision oncology, making advanced molecular testing accessible, efficient, and reliable for laboratories worldwide.